Table 4.
Crude and adjusted hazard ratios for the association between a variable and the risk of NTM infection within the 1st year after the diagnosis
| Univariate analysis | Model A | Model B | ||||
|---|---|---|---|---|---|---|
| HR | (95%CI) | HR | (95%CI) | HR | (95%CI) | |
| Group | ||||||
| Non- SS | Reference | Reference | Reference | Reference | Reference | Reference |
| SS | 16.06 | (3.24–79.60) | 5.22 | (0.71–38.64) | ||
| SS treated without immunosuppressants | 6.28 | (0.65–60.42) | 4.04 | (0.39–41.85) | ||
| SS treated with immunosuppressants | 72.39 | (12.09–433.31) | 33.33 | (4.37–254.23) | ||
| Age | ||||||
| < 50 years | Reference | Reference | Reference | Reference | Reference | Reference |
| ≥ 50 years | 2.66 | (0.31–22.76) | 1.60 | (0.17–15.09) | 1.61 | (0.17–15.25) |
| Gender | ||||||
| Female | Reference | Reference | Reference | Reference | Reference | Reference |
| Male | 3.81 | (0.70–20.79) | 2.92 | (0.53–16.19) | 2.85 | (0.51–15.80) |
| CCI group | ||||||
| 0 | Reference | Reference | Reference | Reference | Reference | Reference |
| ≥ 1 | 6.89 | (1.26–37.61) | 4.05 | (0.67–24.28) | 4.16 | (0.69–24.98) |
| Medications | ||||||
| Immunosuppressants | 39.16 | (7.17–213.81) | 6.21 | (0.75–51.40) | ||
| Steroid | 6.94 | (1.27–37.90) | 2.55 | (0.37–17.46) | 2.65 | (0.38–18.24) |
Immunosuppressants: methotrexate, cyclophosphamide, or azathioprine. Abbreviations: SS Sjögren’s Syndrome, CCI Charlson comorbidity index